Last reviewed · How we verify
13-valent pneumococcal vaccine
13-valent pneumococcal vaccine is a Biologic drug developed by Pfizer. It is currently FDA-approved. Also known as: Prevenar 13.
At a glance
| Generic name | 13-valent pneumococcal vaccine |
|---|---|
| Also known as | Prevenar 13 |
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 13-valent pneumococcal vaccine CI brief — competitive landscape report
- 13-valent pneumococcal vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about 13-valent pneumococcal vaccine
What is 13-valent pneumococcal vaccine?
13-valent pneumococcal vaccine is a Biologic drug developed by Pfizer.
Who makes 13-valent pneumococcal vaccine?
13-valent pneumococcal vaccine is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
Is 13-valent pneumococcal vaccine also known as anything else?
13-valent pneumococcal vaccine is also known as Prevenar 13.
What development phase is 13-valent pneumococcal vaccine in?
13-valent pneumococcal vaccine is FDA-approved (marketed).
Related
- Manufacturer: Pfizer — full pipeline
- Also known as: Prevenar 13
- Compare: 13-valent pneumococcal vaccine vs similar drugs
- Pricing: 13-valent pneumococcal vaccine cost, discount & access